Electrochemical sensors have an inherent advantage for being simple, cheap (glucometers), especially for nucleic acid assays. Yet there are very few health devices in the market for point of care applications. Further, there is significant & growing interest in various other assay platforms as well, when electrochemical sensors by themselves seem very advantageous compared to multistep assay formats.
Would appreciate if someone can help me understand why is this?
I think one of the reason might be that immunoassays usually have low limit of detection.
My personal opinion is that most of these systems do not work reliably in practice. It is a huge difference to perform a biosensor measurement in the lab compared to the "field" when no expert is around to fix any issues.
Might also be worth to notice the cost and hurtles with FDA approvals. If I'm no mistaken, some of the technology was approved just around june of 2018.
- Badges
- Science method
- Similar topics
- Biological Science
- Immunology
- Immunology Techniques
- Immunoassay